摘要
目的探讨PTPN12在乳腺癌中的表达情况及其影响指标。方法选取2011年1月~2012年12月于汕头大学医学院第一附属医院诊治的60例乳腺癌患者为观察组,并选取同时期60例乳腺良性疾病患者为对照组,统计及比较两组患者的PTPN12阳性表达率;比较观察组不同PTPN12表达情况患者的生存期;比较观察组中不同分子分型、EGFR及VEGFR-3表达情况乳腺患者的PTPN12阳性表达率。结果观察组患者的PTPN12表达总阳性率低于对照组,且观察组中PTPN12阳性者的生存期长于PTPN12阴性者,同时观察组中不同分子分型、EGFR及VEGFR-3表达情况者的PTPN12表达总阳性率比较,差异均无统计学意义(均P<0.05)。结论 PTPN12在乳腺癌中的表达呈现明显异常的状态,且其表达与患者的预后存在一定的关系,应重视对乳腺癌患者PTPN12的检测与干预。
Objective To investigate the expression situation of PTPN12 in the patients with breast cancer and its influence indexes. Methods Sixty patients with breast cancer in the First Affiliated Hospital of Shantou University Medical College from January 2011 to December 2012 were selected as the observation group, 60 patients with breast benign lesions at the same period were selected as the control group. The positive expression rate of PTPN 12 in the two groups was counted and compared; the survival time of patients with different expression situation of PTPN12 in the observation group were compared; the positive expression rate of PTPN12 in the observation group with different molecular typing, EGFR and VEGFR-3 expression situation were compared. Results The total positive expression rate of PTPN12 in the observation group was lower than that of control group, and the survival time of patients with positive expression of PTPN12 in the observation group were longer than those with negative expression of PTPN12, the total positive expression rate of PTPN12 in the observation group with different molecular typing, EGFR and VEGFR-3 expression situation had statistically significant differences （P 〈 0.05）. Conclusion The expression of PTPN 12 in the patients with breast cancer shows obviously abnormal expression state, and the expression has relationship with the prognosis of patients, so the PTPN12 detection and intervention of patients with breast cancer should be paid more attention.
作者
郑耿龙
麦瑞琴
郑高哲
吴映娥
ZHENG Genglong MAI Ruiqin ZHENG Gaozhe WU Ying＇e(The First Affiliated Hospital of Shantou University Medical College, Guangdong Province, Shantou 515041, China)
出处
《中国医药导报》
CAS
2017年第5期90-93,共4页
China Medical Herald
基金
国家自然科学基金资助项目(81402616)
